anp chart, page-670

Not much
Sarepta has to complete their on going trial to be finalised by years end and show meaningful efficacy .FDA and Sarepta agreed to look for a primary endpoint: related to walking 4 to 7 year olds given the gene therapy.
Sarepta want accelerated approval Re making micro Dystrophen before results prove walking efficacy.
The primary cause of DMD is the loss of dystrophen
Which Sarepta is trying to make ( micro Dystrophen)
The Market is very small if they are successful.
Remember our market is the non ambulant boys

The other thing Sarepta has to show efficacy with the other 3 drugs : Not forth coming
FDA has to show the Biotech world that you have to prove a drug will benefit a disease: otherwise it will not be approved.
So Jakalo: no threat to Atl1102